Based on current phase 3 TRIUMPH trial timelines, a regulatory submission to the MHRA is not anticipated before 20262027 at the earliest, with a possible marketing authorisation in 20272028 and NHS availability potentially from 2028 onwards, subject to NICE appraisal
Ozempic 0.25 mg solution for injection in pre-filled pen Patient Information Leaflet
Professional Medical Disclaimer: Always consult a qualified healthcare professional, including your primary care physician or a licensed clinician, before starting, stopping, or changing any prescription treatment, including GLP-1 medications
You need to balance appetite suppression (which helps with fat loss) against nutritional adequacy (which prevents muscle loss)
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others Change history 28 May 2025 A Correction to this paper has been published: References Drucker, D
They're strategic about WHAT they eat, WHEN they eat, and HOW they manage the side effects